ALX ONCOLOGY HOLDINGS reports a Return on Equity (ROE) of -58.72%.

What is ALXO's dividend yield?

ALX ONCOLOGY HOLDINGS offers a dividend yield of 0.00%.

What is ALXO's Deepscope Quality Score?

Deepscope rates ALXO's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ALXO?

Deepscope's AI Timing Score for ALXO is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ALXO belong to?

ALX ONCOLOGY HOLDINGS is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

ALXO (NASDAQ) Stock Analysis | ALX ONCOLOGY HOLDINGS

Stock Check Daily update data at 9:30 AM
(Price: 2026-06-05 | FS: 2026-03-31)

ALXO

ALX ONCOLOGY HOLDINGS

US:NASDAQ STOCK Healthcare >> Biotechnology News 79

USD 1.54

-0.02 (-1.28%) Day Change

Watchlist Portfolio Compare Chart

0.06

D/E

-58.7%

ROE

-49.8%

ROA

0.00%

Div Yield

ALX ONCOLOGY HOLDINGS
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 1.54 Price -0.02 (-1.28%) Day Change	NEWS SCORE: 79

ALXO, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

47%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	79
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	1.54
PBV / Sector	1.39 / 4.63 GOOD
Earning Per Share	-0.65

PE / Sector	N/A / 17.43
PEG or PE/Growth / Sector	N/A / 0.53
Average 1M Daily Value	2.07 M GREAT
Average 1W Daily Value	2.06 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 449.48
NPM Average (%) / Sector	N/A / -1,506.49
NPM Change Average (%) / Sector	N/A / 4,940.99
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-49.83 / 30.58
ROA Average (%) / Sector	-83.98 / -347.17
ROA Change Average (%) / Sector	29.97 / 5,125.52 GREAT
ROE (%) / Sector	-58.72 / -3.58
ROE Average (%) / Sector	-140.09 / 40.65
ROE Change Average (%) / Sector	66.42 / 2,109.80 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.49
Dividend Change Average (%) / Sector	N/A / 4.17

Registration Details

Analyze Date	2026-06-06 09:08:26
Symbol	ALXO
Name	ALX ONCOLOGY HOLDINGS
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	134.56 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	209.92 / 8,857.28

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 323 Allerton Avenue, South San Francisco, CA, United States, 94080

Phone: 650 466 7125

Website: https://www.alxoncology.com

Sector: Healthcare >> Biotechnology

Description: ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.